Fulcrum Therapeutics Q2 EPS $(0.38) Beats $(0.44) Estimate, Sales $880.00K Miss $1.60M Estimate
Portfolio Pulse from Benzinga Newsdesk
Fulcrum Therapeutics reported Q2 losses of $(0.38) per share, beating the analyst consensus estimate of $(0.44) by 13.64%. However, the company's quarterly sales of $880.00K missed the analyst consensus estimate of $1.60M by 45.00%.
August 04, 2023 | 12:55 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Fulcrum Therapeutics' Q2 earnings beat estimates but sales missed, which could lead to mixed market reactions.
Fulcrum Therapeutics reported better than expected Q2 earnings per share, which is positive for the stock. However, the company's sales missed estimates, which is negative. These two factors could offset each other, leading to a neutral short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100